trending Market Intelligence /marketintelligence/en/news-insights/trending/qm7OaA5qpGIrh7Zh_x7SrA2 content esgSubNav
In This List

Astellas Pharma's blood cancer drug gets US FDA fast track designation

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Astellas Pharma's blood cancer drug gets US FDA fast track designation

The U.S. Food and Drug Administration granted fast-track designation to Astellas Pharma Inc.'s gilteritinib to treat a certain type of blood cancer.

The designation covers the company's study of gilteritinib in adult patients with FLT3+ relapsed or refractory acute myeloid leukemia.

Astellas Pharma said four phase 3 trials of gilteritinib in various AML patient populations are underway.

Gilteritinib is an investigational compound discovered through a research collaboration between Astellas Pharma and Kotobuki Pharmaceutical Co. Ltd.

Astellas has exclusive global rights to the drug.